NewAmsterdam Pharma NAMS 深 沪
等待开盘 10-09 09:30:00 美东时间
21.26
-0.870
-3.93%
华盛通- 最 高22.13
- 今 开22.00
- 成交量 166.51万股
- 最 低 20.91
- 昨 收 22.13
- 总市值 25.41亿
- 52周最高 42.205
- 市盈率 静 --
- 换手率 1.39%
- 52周最低 20.91
- 委 比 -87.86%
- 总股本 1.20亿
- 历史最高 42.205
- 量 比 1.19
- 振 幅 5.51%
- 历史最低 5.6326
- 每 手 1
- 风险率 4.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
NewAmsterdam Pharma Announces Dosing Of First Participant In SPINOZA, Phase 2b Clinical Trial Evaluating Obicetrapib In Individuals With Preclinical Alzheimer’s Disease
NewAmsterdam Pharma Announces Dosing Of First Participant In SPINOZA, Phase 2b Clinical Trial Evaluating Obicetrapib In Individuals With Preclinical Alzheimer’s Disease
09-29 20:03
EU Approval of Obicetrapib Products Strengthens NewAmsterdam
An update from NewAmsterdam Pharma Company ( ($NAMS) ) is now available. On Sep...
09-22 05:22
NewAmsterdam Pharma Receives Marketing Authorization From European Commission For Ubeslo, Evlarco To Treat Primary Hypercholesterolaemia
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom exis...
09-21 21:03
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
The European Commission has granted marketing authorization for Ubeslo® and Evlarco®, the first regulatory approval of obicetrapib globally, developed by NewAmsterdam Pharma and Menarini Group. These therapies, supported by Phase 3 trials, significantly reduce LDL-C levels with favorable tolerability, offering new treatment options for patients with elevated LDL-C. NewAmsterdam and Menarini will advance obicetrapib's development and commercializa...
09-21 13:00
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 400 points on Tuesday. Shares of Novartis AG (NYSE:NVS) fell sharply in pre-market trading after the company disclosed that the pelacarsen phase III Lp(a) HORIZON trial did not meet its primary endpoint. Novartis shares tu...
09-08 20:01
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target
HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and maintains $52 price target.
09-08 18:36
Biggest stock movers Tuesday: ZIM, NVS, and more
Stock futures edged lower Tuesday morning as Brent crude holds above $98 a barrel amid Iranian threats against Gulf oil and gas infrastructure. Here are some of Tuesday's biggest stock movers: Biggest...
09-08 17:23
